Pluvicto cost: Financial assistance options, savings, more

If you’ve ever opened a medical bill and felt your soul briefly leave your body, you’re not alone.
Pluvicto (a targeted radioligand therapy for certain advanced prostate cancers) can be life-extendingand
also eye-wateringly expensive. The good news: many patients don’t pay the “headline” price, and there are
legitimate ways to reduce out-of-pocket costs through insurance strategy, manufacturer programs, nonprofit
grants, and hospital financial services.

This guide breaks down what Pluvicto can cost, why the numbers vary so much, and how people commonly
piece together savings options. It’s not legal or medical advice (and it can’t replace your oncology team or
a financial counselor), but it will help you ask smarter questions and avoid the “surprise invoice jump-scare.”

What Pluvicto is (and why it’s priced differently than most cancer drugs)

Pluvicto is a radiopharmaceutical treatment that targets prostate-specific membrane antigen (PSMA), a protein
often found in higher amounts on prostate cancer cells. Think of it as a guided delivery system: it binds to
PSMA-positive cancer cells and delivers radiation to damage those cells.

Pluvicto isn’t typically something you pick up at a retail pharmacy. It’s administered in a specialized setting
(often a hospital outpatient department or nuclear medicine-capable center) and follows a scheduled dosing
plancommonly every 6 weeks, for up to 6 doses depending on your situation and how you tolerate treatment.

Before treatment, many patients are selected using a PSMA PET scan (often with an FDA-approved imaging agent).
That scan matters clinicallyand financiallybecause imaging and related visits can add meaningful cost beyond
the drug itself.

How much does Pluvicto cost?

Here’s the headline number people hear most often: the wholesale acquisition cost (WAC), sometimes described as
the “list price,” has been widely reported around $42,500 per dose. A full course can be up to
6 doses, so the drug-only math can land around $255,000 for a complete course
(again: drug-only, not total care).

Why “drug-only” is not the same as “total treatment cost”

Even if your insurance covers Pluvicto, you may still see additional charges tied to:

• PSMA PET imaging (the scan and the imaging agent)
• Facility fees (especially in hospital outpatient settings)
• Professional fees (physician/nuclear medicine services)
• Lab work and monitoring (blood counts, kidney function, follow-up visits)
• Supportive medications (for side effects, if needed)
• Travel costs if the nearest administering site isn’t close

That’s why two patients can both receive Pluvicto and end up with wildly different “bottom line” totals.
The drug price is only one piece of the financial puzzle.

Why your bill may not match the “$42,500” number

In U.S. healthcare, the number you hear on the internet is rarely the number anyone actually pays.
What matters is your insurer’s allowed amount (the negotiated or regulated reimbursement),
plus your plan’s rules for deductibles, coinsurance, copays, and out-of-pocket maximums.

Pluvicto is billed differently than many drugs

Pluvicto is commonly billed under the HCPCS code A9607. Billing may be based on “units”
that correspond to the administered activity (for example, a 200 mCi dose can translate into 200 billable units
under certain payer billing approaches). This can look confusing on an itemized bill, but it’s one reason the
claim line items can appear large and technical.

Site of care can change cost-sharing

A big cost driver is where you receive treatment:

• Hospital outpatient may carry facility fees and different cost-sharing than a physician office.
• Medicare Advantage and some commercial plans may have different copays/coinsurance depending
  on network status and site of care.

Translation: the same medicine can produce different out-of-pocket costs based on the billing settingeven
within the same city.

What you might pay out of pocket (by insurance type)

If you have commercial insurance (employer or marketplace)

Commercial coverage often involves some combination of:

• Annual deductible (what you pay before coverage kicks in)
• Coinsurance (a percentage of the allowed amount)
• Out-of-pocket maximum (a cap after which covered services may be paid at 100% for the year)

For high-cost therapies, a common pattern is: you hit the out-of-pocket maximum early in the year, then
covered care becomes much less expensive for the remainder of that plan year. That can be “good” financially,
but it’s still painful at the startlike ripping off a Band-Aid made of invoices.

Many commercial plans require prior authorization for Pluvicto, and they may require proof of
eligibility criteria (such as PSMA positivity and prior therapies). Delays are common, so starting the paperwork
early can reduce gaps in care.

If you have Medicare (Original Medicare)

Because Pluvicto is administered in a clinical setting, it’s often covered under Medicare Part B
(not Part D). Under Original Medicare, once you meet the annual Part B deductible, you generally pay
20% coinsurance of the Medicare-approved amount for covered Part B services and drugs.

Important detail for planning: the 2026 Medicare Part B deductible is $283. The deductible is
small compared to the coinsurance risk on expensive treatments, which is why supplemental coverage matters.

If you have a Medigap (Medicare Supplement) plan, it may cover some or most of that 20%
coinsurance depending on the plan type. If you don’t have Medigap (or another secondary coverage),
the coinsurance exposure can be substantial.

If you have Medicare Advantage (Part C)

Medicare Advantage plans replace Original Medicare’s cost structure with plan-specific copays/coinsurance,
networks, and authorization rules. You’ll want to ask:

• Is the administering center in-network?
• Is Pluvicto covered as a Part B drug under the plan?
• What is my coinsurance (and is there a per-treatment cap)?
• Do I need prior authorization and what documentation is required?

If you have Medicaid

Medicaid coverage varies by state, but many states cover medically necessary oncology treatments with
prior authorization and specific billing requirements. Out-of-pocket costs can be lower than commercial
plans, but access may depend on provider participation and state policy rules.

If you’re uninsured or underinsured

The highest financial risk is often in the uninsured/underinsured groupbut there are also programs designed
specifically for this situation. Hospital charity care, manufacturer patient assistance, and nonprofit grants
can be especially important here.

Financial assistance and savings options to explore

1) Start with your hospital or cancer center financial counselor

This is the most underrated cost-saving move. Ask for a written cost estimate that includes:

• The expected number of Pluvicto doses
• Where the treatment will be billed (hospital outpatient vs other setting)
• Imaging costs (PSMA PET scan and related services)
• Your plan’s expected deductible/coinsurance responsibility

Then ask if the hospital offers:
financial assistance/charity care, income-based discounts, or
payment plans. Even insured patients may qualify for certain discounts depending on income
and medical debt burden.

2) Novartis Patient Support and co-pay savings (commercial insurance)

The manufacturer offers a support pathway that can help with benefits verification, navigating coverage steps,
andif you have commercial insurancepotential co-pay savings programs.

A key limitation: co-pay savings programs are typically not available for patients enrolled in
Medicare, Medicaid, or other federal/state programs. (This is common across the industry, not unique to Pluvicto.)
If you do qualify (commercial insurance), assistance may have a maximum benefit limit per course of treatment,
so you’ll want to ask for the current terms and what counts as “eligible out-of-pocket.”

3) Novartis Patient Assistance Foundation (NPAF)

For patients who meet eligibility requirements (often based on insurance status, income, and other criteria),
a manufacturer-affiliated independent foundation may provide medication at no cost. These programs are
paperwork-heavy but can be a game-changer for patients who otherwise could not access treatment.

Tip: apply early and gather documents in advance (proof of income, insurance status, and prescription details).
The fastest applications are the ones that are complete the first timebecause nothing slows a process like
“missing page 2 of 2.”

4) Independent nonprofit co-pay foundations (often helpful for Medicare patients)

If you have Medicare and face high coinsurance, independent charities may offer grants that can help cover
copays/coinsurance/deductibles for eligible patients. Availability changes throughout the yearfunds can
open, close, and reopen depending on donations.

Organizations commonly referenced for prostate cancer financial help include:

• CancerCare Co-Payment Assistance Foundation (prostate cancer fund; grant caps and availability vary)
• PAN Foundation (prostate cancer fund; may offer annual assistance when open)
• Patient Advocate Foundation Co-Pay Relief (fund status can change)
• HealthWell Foundation (some funds may assist Medicare beneficiaries with prostate cancer costs)
• Good Days (may cover certain diagnoses such as metastatic castrate-resistant prostate cancer when funded)
• The Assistance Fund (program availability varies)

Practical advice: if a fund is closed today, don’t assume it’s closed forever. Ask to be notified, check regularly,
and ask your clinic’s financial navigator which foundations tend to fund your diagnosis category.

5) Travel, transportation, and lodging support

Pluvicto isn’t offered everywhere. If you need to travel to a qualified center, you may be able to reduce
non-medical costs through programs such as:

• American Cancer Society Road To Recovery (free rides to cancer-related appointments in some areas)
• American Cancer Society Hope Lodge (free lodging for eligible patients/caregivers when treatment is far from home)

Even small savings here matter. Gas, hotels, parking, and missed work don’t show up as “medical charges,”
but they absolutely show up in real life.

6) “Find me help” tools and prostate cancer organizations

If you don’t know where to begin, search tools and advocacy organizations can point you toward programs that
match your situation:

• Medicine Assistance Tool (MAT) (a search engine for patient assistance resources)
• Prostate Cancer Foundation and ZERO Prostate Cancer (financial resource directories and guidance)

How to actually lower your costs: a step-by-step playbook

Step 1: Ask for an itemized estimate before the first dose

Ask the billing team for the expected coding and where you’ll receive treatment. If your plan has different
cost-sharing for hospital outpatient vs other settings, this single detail can change your out-of-pocket cost.

Step 2: Confirm authorization and network status (in writing)

Get confirmation that:

• The facility is in-network (if you have a network plan)
• Prior authorization is approved for the intended number of doses
• PSMA PET imaging (and the imaging agent) is authorized if required

Step 3: Match assistance to your insurance type

• Commercial insurance: ask about manufacturer co-pay savings and your plan’s out-of-pocket maximum.
• Medicare: explore Medigap/secondary coverage (if available to you) and independent co-pay foundations.
• Uninsured: ask the hospital about charity care and apply to patient assistance foundations quickly.

Step 4: Keep a simple “money folder”

Boring but powerful. Keep:

• Authorization letters
• Explanation of Benefits (EOBs)
• Itemized bills
• Foundation award letters
• A one-page log of who you called, when, and what they said

This helps you catch billing errors and prove what was approved. (Healthcare systems are amazing.
Paperwork systems are… a work in progress.)

Common questions people ask about Pluvicto cost

Is Pluvicto covered by insurance?

Many insurers cover Pluvicto when medical criteria are met, but coverage commonly requires prior authorization
and documentation (for example, PSMA-positive disease and prior therapies). Coverage details depend on your plan.

Can I use a co-pay card if I have Medicare?

Typically, no. Manufacturer co-pay programs are generally limited to patients with commercial insurance and
exclude Medicare/Medicaid and other government programs. Independent foundations are often the alternative path
for Medicare patients.

What’s the fastest way to learn what I’ll personally pay?

Ask your treatment center for a pre-treatment estimate and ask your insurer for a
benefit breakdown for the site of care where you’ll be treated. Bring those two numbers
together with your financial navigator and ask what assistance can be applied.

Does timing matter?

Yes. For commercial plans, out-of-pocket spending resets each plan year. For independent foundations, funding
opens/closes during the year. For everyone, starting benefits verification early can prevent delays.

Bottom line

Pluvicto is expensive, and the sticker shock is real. But the “real cost” depends on insurance coverage,
where you receive treatment, and whether you can layer legitimate assistance optionshospital financial help,
manufacturer support for eligible patients, and independent co-pay foundations.

The most practical next step is also the simplest: ask your clinic to connect you with a financial navigator
and request a written estimate before the first dose. You deserve clear numbers, not mystery math.

Real-world cost & assistance experiences (what it often looks like)

The financial side of Pluvicto tends to feel like a second jobone you didn’t apply for and can’t quit.
While everyone’s situation is different, here are realistic examples of how patients and caregivers often
describe the process (shared as common scenarios, not as any one person’s story).

Experience 1: “We hit the out-of-pocket max in record time.” (Commercial insurance)

A common commercial-insurance pattern is that the first one or two treatment-related claims trigger a deductible
and coinsurance that feels enormous. People often describe the first month as financially brutal, followed by a
strange calm once the out-of-pocket maximum is reached. That’s why some families plan cash flow around the
beginning of the yearsetting aside funds (if possible), spacing optional care, and asking whether supportive
imaging or labs can be coordinated to avoid duplicate billing.

In this scenario, manufacturer co-pay savings (for eligible commercially insured patients) may reduce the
immediate out-of-pocket hit. But patients frequently learn there’s a maximum assistance amount, so they ask
early: “What’s covered, what’s excluded, and what happens when the cap is reached?”

Experience 2: “Medicare covered it, but the 20% was terrifying.” (Original Medicare)

Medicare patients often expect coverage to mean “no big bill,” and then get surprised by coinsurance exposure.
Many people describe the turning point as meeting with a financial navigator who explains the role of Medigap,
secondary coverage, and independent foundations. When a co-pay foundation is open and the patient is eligible,
that grant can transform the situationturning a scary unknown into a manageable plan.

People also report that persistence matters: a foundation may be closed one week and open the next. Clinics that
regularly treat prostate cancer often know which funds are most relevant and how to apply quickly when funding
reappears.

Experience 3: “The travel costs were the sneak attack.” (Any insurance type)

Because Pluvicto requires specialized administration, some patients travel hours to reach a capable center.
Even when the medical claims are covered, families describe the add-on costsgas, parking, lodging, meals,
and time off workas surprisingly heavy. In these cases, transportation and lodging programs (plus local
nonprofit resources) can make treatment logistically possible, not just medically appropriate.

Experience 4: “The paperwork was worse than the math.” (Everyone, everywhere)

Nearly everyone says the same thing: the hardest part is not understanding the numbersit’s chasing the
documents. People who feel most in control tend to do three simple things: keep a folder, write down every call,
and ask for decisions in writing. They also learn to separate the “EOB” (what insurance processed) from the
“bill” (what a provider is requesting), because those are not always the same thing.

The most helpful mindset shift is treating financial navigation like a care task, not a side quest. Ask for help,
delegate calls when possible, and remember: you’re not being “difficult” by requesting clarity. You’re being
responsiblebecause cancer is hard enough without surprise billing as a bonus boss fight.